| Date |
Subject |
Media |
| 2025-07-15 |
New Biomedical Player Joins the Market: LotusNine Medical Debuts on the Pioneer Stock Board, Focusing on Mobile AI Medical Devices
|
The Taipei Exchange’s Pioneer Stock Board welcomes a new addition in the biotech and healthcare category. LotusNine Medical Inc., a company integrating AI to develop innovative mobile medical devices and risk detection platforms, officially listed today (July 2). |
| 2025-07-15 |
Primo Biotechnology Completes Series A Funding, Targets Emerging Stock Board Listing by 2026
|
As global pharmaceutical giants Eli Lilly, AstraZeneca, and Novartis aggressively expand into the radiopharmaceutical market, Taiwan-based startup Primo Biotechnology Co., Ltd. is gaining momentum, announcing the successful completion of its Series A funding round. |
| 2025-07-15 |
Immunwork’s Long-Acting Octreotide Drug TE-8214 Shows Promising Results in Phase 1 Clinical Trial
|
Immunwork, founded by renowned immunologist Tse Wen Chang, announced on July 1 that its independently developed long-acting octreotide candidate TE-8214 has successfully completed its Phase 1 clinical trial in Australia. The results demonstrated good safety and tolerability, with the drug achieving its intended pharmacological mechanism. Additionally, subcutaneous injection was well tolerated and did not cause any injection-site reactions. |
| 2025-07-15 |
HanchorBio Licenses Immuno-Oncology Drug HCB101 to Shanghai Henlius in a Deal Worth Up to USD 202 Million
|
HanchorBio, a Taiwan-based biotech company specializing in innovative immuno-oncology therapies, announced on June 30 that it has entered into an exclusive regional licensing agreement with Shanghai Henlius Biotech, Inc. The deal includes a $10 million upfront payment and up to $192 million in milestone payments, for a total potential value of $202 million. The agreement covers the development and commercialization of HCB101 across Mainland China, Hong Kong, Macau, selected Southeast Asian countries, and the entire MENA region (Middle East and North Africa). This collaboration marks a significant milestone for Taiwan’s homegrown oncology drug development on the international stage. |
| 2025-07-15 |
Tanvex BioPharma Breaks into U.S. Market with First Biosimilar, Licensed for 2025 Launch
|
Tanvex BioPharma, a subsidiary of the Bora Group, announced yesterday (June 30) that it has licensed its biosimilar NYPOZI to U.S.-based pharmaceutical company Invagen for commercial sales in the United States. Industry insiders note that this marks a new chapter for Tanvex, as it officially enters the global market with product launches expected to generate revenue, royalties, milestone payments, and profit-sharing income. |
| 2025-07-15 |
PURIBLOOD MEDICAL to Establish Domestic Blood Bag Supply Chain as Product Gains Strategic Material Status
|
PURIBLOOD MEDICAL, the only domestic manufacturer of blood bags and leukocyte reduction filters in Taiwan, announced on June 30 that it is ready to begin production at the nation’s first blood bag manufacturing facility in Shulin, built in collaboration with Nan Ya Plastics through a technology transfer. The facility has an initial production capacity of 8 million blood bags and 2.8 million sets of blood bag filter kits. Once the in-line filter kit product receives certification, it will be immediately available to meet national demand. |
| 2025-07-15 |
CHLITINA-KY Targets Steady Quarterly Growth in 2025 through Brand Expansion, Product Innovation, and New Customer Acquisition
|
CHLITINA Holding Limited (CHLITINA-KY) is aligning its operations with the growing demand in the premium anti-aging market, while actively responding to the rise of new retail and evolving consumer behaviors. In addition to launching multiple new products, the company is strengthening its live commerce strategy through official livestreams, in-house broadcasting teams, and collaborations with key opinion leaders (KOLs) to boost product visibility and conversion. In 2025, CHLITINA aims to drive growth by expanding its brand portfolio, introducing new products, and acquiring new customers. With supportive policies under China’s “seeking progress while maintaining stability” approach, the company expects revenue to grow steadily, achieving its goal of quarter-over-quarter improvement. |
| 2025-07-14 |
OBI Pharma Focuses on ADC as Core Growth Strategy
|
At the shareholders’ meeting on the 27th, OBI Pharma CEO Heidi Wang announced that following the termination of the Globo H program, the company has realigned its strategy to concentrate on antibody-drug conjugate (ADC) products and platform technology licensing as its primary growth driver moving forward. |
| 2025-07-14 |
TCM BIOTECH Continues New Drug and Innovative Medical Device Development; 2025 Operations Expected to Surpass Last Year
|
At its shareholders’ meeting on the 27th, TCM BIOTECH approved the 2024 financial statements and dividend distribution plan, proposing a cash dividend of NT$0.35 per share. Chairman Huan-Ching Hsu stated that although revenue declined last year due to adjustments in production and sales structure, overall profitability still grew. For 2025, cumulative consolidated revenue through May decreased by 2.17% year-on-year; however, May alone showed strong growth with monthly revenue up 34.65% and year-on-year growth of 22.08%, reflecting robust double-digit monthly and yearly increases. With continued benefits from product mix adjustments, second-half performance is expected to surpass the first half. |
| 2025-07-14 |
TaiRx Advances Dual Track of New Drugs and Health Products with Comprehensive International Collaboration
|
TaiRx, a biopharmaceutical company, is progressing on two fronts: new drug development and health products. Following the U.S. FDA orphan drug designation granted to its small-molecule anticancer drug CVM-1118, the company has attracted multiple international pharmaceutical companies for partnership discussions. The next step involves initiating multinational, multi-center clinical trials targeting neuroendocrine tumors (NET) in collaboration with major industry players. Meanwhile, the selenium injection and health supplement businesses continue to expand, with a flagship health product scheduled for a major launch in mid-August and a high-dose packaging version of the selenium injection “Xiningte” planned for release next year. |
